Allakos (id:8065 ALLK)
0.880 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 1:56:05 PM)
Exchange closed, opens in 19 hours 33 minutes
-1.12 USD (-1.12%)
-23.48 USD (-23.48%)
35.38 USD (35.38%)
-38.46 USD (-38.46%)
-50.56 USD (-50.56%)
-99.00 USD (-99.00%)
-96.76 USD (-96.76%)
About Allakos
Market Capitalization 81.03M
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
| Headquarters (address) |
825 Industrial Road San Carlos 94070 CA United States |
| Phone | 650 597 5002 |
| Website | https://www.allakos.com |
| Employees | 131 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ALLK |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.540 - 3.41 |
| Market Capitalization | 81.03M |
| P/E trailing | -0.411 |
| P/E forward | -1.44 |
| Price/Book | 1.11 |
| Beta | 1.02 |
| EPS | -2.03 |
| EPS United States (ID:6, base:3402) | 24.22 |